The conversation discusses the effectiveness of topical Rapamycin for hair regrowth and color restoration. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.
Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.
The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.
The user experienced significant hair regrowth using finasteride, minoxidil, and microneedling but later faced rapid thinning despite consistent treatment. They plan to switch from finasteride to dutasteride and consider oral minoxidil if the situation doesn't improve.
Dutasteride doses matter for hair loss treatment and are more effective than finasteride. RU58841 is suggested for better gains, but side effect profiles should be considered.
In the US, Amazon Pharmacy offers unlimited generic Finasteride and Dutasteride for $5/month with RxPass, requiring an Amazon Prime membership and a prescription. Alternatives include Costco and other pharmacies, but prices and availability vary.
Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.
The conversation is about finding a source for RU58841 in Canada as an additional treatment for hair loss, alongside oral minoxidil and dutasteride. Alternatives like kx826 are suggested, with some users discussing prices and sources for these products.
The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.
The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.
A user plans to switch from finasteride to dutasteride for better hair loss treatment, citing dutasteride's higher DHT suppression. Others share mixed experiences, discussing transition methods, shedding, and potential side effects.
User shared progress with RU 58841, Minox, and Dutasteride 3 times a week for hair loss. Others noticed improvements and expect great gains over the next year.
A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.
RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
A user switched from finasteride to dutasteride, experiencing significant shedding initially but noticing improved hair health and thickness over time. They also use minoxidil, both oral and topical, and report no significant side effects from the treatments.
The user is exploring hair loss treatments and is interested in procyanidin B2 and annurca apples but has concerns about the effectiveness and availability of supplements. They cannot use Dutasteride or Finasteride and are considering Minoxidil with microneedling.
After 8 months of using topical finasteride, hair miniaturization continues, raising concerns about its effectiveness. Microneedling is suggested as a possible complementary treatment.
The user is using finasteride, RU58841, and various natural supplements and treatments like seamoss, fish oil, and black rice water spray to combat hair loss, avoiding minoxidil due to dependency concerns. They report thicker hair and regained confidence, while discussing the potential risks and benefits of RU58841 with others.
Dutasteride is favored over finasteride by some for better hair loss reversal, improved skin, and fewer side effects, though individual responses vary. It may also help with dandruff and eczema but has a slightly higher risk of gynecomastia.
The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.